Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy

Advances in Therapy

Volumn 23, Issue 4, 2006, Pages 534-542

  Alici, Suleyman ^a   Bavbek, Sevil ^a   Basaran, Mert ^a   Onat, Haluk ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Aggressive non Hodgkin's lymphoma; Prognostic factors; Refractory

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MITOGUAZONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER INVASION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT RESPONSE; TURKEY (REPUBLIC);

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750972014     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850042     Document Type: Article

References (29)

1. Armitage JO, Cheson BD. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol. 1988;6:1335-1347.
2. Cavalli F. Treatment of lymphomas. Baillieres Clin Haematol. 1991;4:157-179.
3. Fisher RI, Gaynor ER, Dahlberg MS, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
4. Davidson KL, Devaney MB, Tighe JE, et al. A pilot study of CODOX-M/IVAC in primary refractory or relapsed high-grade non-Hodgkin's lymphoma: a Scotland and Newcastle Lymphoma Group Study. Haematologia. 2003;88:1366-1371.
5. Cabanillas F, Velasquez WS, McLaughlin P, et al. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease. Semin Hematol. 1988;25:47-50.
6. Cabanillas F, Hagemeister F, Bodey GP, Freireich EJ. IMVP-16, an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982;60:693-697.
7. Cabanillas F, Hagemeister FB, McLaughlin P, et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987;5:407-412.
8. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatinum in combination with high doses of Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.
9. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4 year follow-up study. J Clin Oncol. 1994;12:1169-1176.
10. Rodriguez MA, Cabanillas FC, Velasquez W, et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol. 1995;13:1734-1741.
11. Kimby E, Brandt L, Nygren P, Glimelius B, for the SBU-group. Swedish Council of Technology Assessment in Health Care: a systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncol. 2001;40:198-212.
12. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
13. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860-1861.
14. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981; 47:207-214.
15. The international non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163-170.
18. Cox DR. The Analysis of Binary Data. New York: Chapman and Hall; 1970.
19. Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018-1026.
20. Josting A, Reiser M, Rueffer U, Salzberger B, Diehl V, Engert A. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure? J Clin Oncol. 2000;18:332-339.
21. Villela L, López-Guillermo A, Montoto S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer. 2001;91:1557-1562.
22. Vose JM, Rowling PA, Lazarus HM, Phillips GL, Armitage JO, Horowitz MM. Multivariate analysis of autotransplant for patients with aggressive non-Hodgkin's lymphoma failing primary induction therapy. Blood. 1997;90(suppl 1):594a.
23. Shipp MA, Abeloff MD, Antman KH, et al. International consensus conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999;10:13-19.
24. Conde E, Sierra J, Iriondo A, et al. Prognostic factors in patients who received autologous bone marrow transplantation for non-Hodgkin's lymphoma: report of 104 patients from the Spanish Cooperative Group GEL/TAMO. Bone Marrow Trans. 1994;14:279-286.
25. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-1545.
26. Haq R, Sawka CA, Franssen E, Berinstein NL. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review. J Clin Oncol. 1994;12:1074-1084.
27. Prince HM, Crump M, Imrie K, et al. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol. 1996;7:1043-1049.
28. Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meuses P, Siegert W. Subclassification of diffuse large B-cell lymphoma according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor. Blood. 1997;89:2291-2297.
29. Baars JW, De Jong D, Willensem EM, Gras L, Dalesio O, Heerde P. Diffuse large B-cell non-Hodgkin's lymphoma: the clinical relevance of histological subclassification. Br J Cancer. 1999;79:1770-1776.